Abstract Number: VPB0319
Meeting: ISTH 2022 Congress
Background: Rituximab is one of the second-line treatments for ITP. At present, there are few studies on low-dose rituximab, lacking of a large number of prospective and randomized trials to support the efficacy and safety of low-dose rituximab, especially in children’s ITP. Influenced by COVID-19, we used two low-dose rituximab regimens before and after March 2020 for second-line treatment of children’s ITP.
Aims: To compare the efficacy and safety of two different regimens for low-dose rituximab of children patients with chronic /refractory ITP, so as to provide basis for clinical treatment.
Methods: 83 children patients were enrolled in this study and non-randomly assigned to receive 100mg/200mg (body weight 30kg) rituximab weekly for 4 weeks (group A, 53 cases) or a single dose of 375mg / m2 rituximab (group B, 30cases). The study was follow-up for at least half a year.
Results: The baseline data of group A and B were the same. For group A: Overall and complete response (OR and CR) rates were 35.8% and 15%, respectively; the side effects rate is 3.8%. In responders, the median time to response was 4 (1 -12) weeks, with a median follow-up time of 36 (14 ~ 46) months, 6 of 19 responders (31.6%) relapsed. For group B: OR and CR rates were 36.7% and 23%, respectively; the side effects rate is 10%. In responders, the median time to response was 1 (1 ~ 4) weeks, with a median follow-up time of 12(6 ~ 19) months, 4 of 11 responders (36.4%) relapsed. No significant difference in the OR, NR, relapse free survival and incidence of side effects was observed in patients between the two groups.
Conclusion(s): The two low-dose rituximab regimens in the treatment of ITP in children both are safe and effective；The single-agent scheme is more recommended because of easier use and not increasing safety events.
To cite this abstract in AMA style:Zhu X. Efficacy and safety of two different low-dose rituximab regimens for Chinese children patients with primary immune thrombocytopenia [abstract]. https://abstracts.isth.org/abstract/efficacy-and-safety-of-two-different-low-dose-rituximab-regimens-for-chinese-children-patients-with-primary-immune-thrombocytopenia/. Accessed September 21, 2023.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/efficacy-and-safety-of-two-different-low-dose-rituximab-regimens-for-chinese-children-patients-with-primary-immune-thrombocytopenia/